Hospital Universitario Puerta de Hierro -ko ikertzaileekin lankidetzan egindako argitalpenak (10)

2021

  1. Gender influence on work satisfaction and leadership for medical oncologists: a survey of the Spanish Society of Medical Oncology (SEOM)

    ESMO Open, Vol. 6, Núm. 2

  2. Multidisciplinary practice guidelines for the diagnosis, genetic counseling and treatment of pheochromocytomas and paragangliomas

    Clinical and Translational Oncology, Vol. 23, Núm. 10, pp. 1995-2019

  3. Sunitinib and Evofosfamide (TH-302) in Systemic Treatment-Naïve Patients with Grade 1/2 Metastatic Pancreatic Neuroendocrine Tumors: The GETNE-1408 Trial

    Oncologist, Vol. 26, Núm. 11, pp. 941-949

2020

  1. The PALBONET Trial: A Phase II Study of Palbociclib in Metastatic Grade 1 and 2 Pancreatic Neuroendocrine Tumors (GETNE-1407)

    Oncologist, Vol. 25, Núm. 9, pp. 745-e1265

2019

  1. Economics of gastroenteropancreatic neuroendocrine tumors: a systematic review

    Therapeutic Advances in Endocrinology and Metabolism, Vol. 10

2018

  1. Prognostic and predictive biomarkers for somatostatin analogs, peptide receptor radionuclide therapy and serotonin pathway targets in neuroendocrine tumours

    Cancer Treatment Reviews, Vol. 70, pp. 209-222

2017

  1. Translational research in neuroendocrine tumors: Pitfalls and opportunities

    Oncogene, Vol. 36, Núm. 14, pp. 1899-1907

2015

  1. Health-related quality of life in well-differentiated metastatic gastroenteropancreatic neuroendocrine tumors

    Cancer and Metastasis Reviews, Vol. 34, Núm. 3, pp. 381-400

  2. Imaging approaches to assess the therapeutic response of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): current perspectives and future trends of an exciting field in development

    Cancer and Metastasis Reviews, Vol. 34, Núm. 4, pp. 823-842

2013

  1. The European medicines agency review of abiraterone for the treatment of metastatic castration-resistant prostate cancer in adult men after docetaxel chemotherapy and in chemotherapy-naïve disease: Summary of the scientific assessment of the committee for medicinal products for human use

    Oncologist, Vol. 18, Núm. 9, pp. 1032-1042